Bioequivalence Study Between Two Oral Formulations of Gemfibrozil Tablets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00800475
Recruitment Status : Completed
First Posted : December 2, 2008
Last Update Posted : August 13, 2013
Information provided by (Responsible Party):
Blu Caribe

Brief Summary:
The purpose of this study is to determine whether two oral formulations of Gemfibrozil Tablets are bioequivalent.

Condition or disease Intervention/treatment Phase
Bioavailability Drug: Gemfibrozil Tablets Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Relative Bioequivalence Study of 600 mg Gemfibrozil Tablets Under Fasting Conditions
Study Start Date : July 2005
Actual Primary Completion Date : July 2005
Actual Study Completion Date : September 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Gemfibrozil
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Test Drug Drug: Gemfibrozil Tablets
Active Comparator: Reference Drug Drug: Gemfibrozil Tablets

Primary Outcome Measures :
  1. Bioequivalence was assessed on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy men or women 18 years of age or older
  • weight within +/- 20% for height and body frame
  • willing to participate and sign a copy of the informed consent form

Exclusion Criteria:

  • recent history of drug or alcohol addiction or abuse
  • pregnant or lactating women
  • history of allergic response to gemfibrozil
  • use of tobacco products
  • evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
  • receipt of any drugs as part of a research study within 28 days prior to study dosing

Responsible Party: Blu Caribe Identifier: NCT00800475     History of Changes
Other Study ID Numbers: R05-0116
First Posted: December 2, 2008    Key Record Dates
Last Update Posted: August 13, 2013
Last Verified: August 2013

Keywords provided by Blu Caribe:

Additional relevant MeSH terms:
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors